Christopher Thomas Wardhaugh

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

Ten Bio Ltd. specializes in providing tailor-made solutions to help clients achieve progress in their skin research programs. The private company is based in Dundee, UK. The British company offers full-thickness human skin with dermal and epidermal layers, appendages, and minor skin cell populations. The company's human skin model, TenSkin™, responds like it would in vivo, delivering predictive results that contribute to a more efficient development process. The company was founded in 2019 by Robyn Hickerson and Michael Patrick Conneely, with Robyn Hickerson serving as CEO since then.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

Ten Bio Ltd. specializes in providing tailor-made solutions to help clients achieve progress in their skin research programs. The private company is based in Dundee, UK. The British company offers full-thickness human skin with dermal and epidermal layers, appendages, and minor skin cell populations. The company's human skin model, TenSkin™, responds like it would in vivo, delivering predictive results that contribute to a more efficient development process. The company was founded in 2019 by Robyn Hickerson and Michael Patrick Conneely, with Robyn Hickerson serving as CEO since then.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

MGB Biopharma Ltd. develops anti-infective medicines. Its lead candidate, MGB-BP-3, is an antibacterial which is active against important multi-resistant and susceptible Gram-positive pathogens. The firm develops an oral formulation of MGB-BP-3 for the treatment of clostridium difficile associated disease. The company was founded by Miroslav Ravic, Gavin David Clark and Raymond Spencer in 2010 and is headquartered in Glasgow, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Lamellar Biomedical Ltd. manufactures basic pharmaceutical products. The firm's offers lamellasomes, a synthetic substance that mimics the actions lamellar bodies and provides treatment for respiratory diseases, such as cystic fibrosis. The company was founded in 2006 and is headquartered in Bellshill, the United Kingdom.

Ten Bio Ltd. specializes in providing tailor-made solutions to help clients achieve progress in their skin research programs. The private company is based in Dundee, UK. The British company offers full-thickness human skin with dermal and epidermal layers, appendages, and minor skin cell populations. The company's human skin model, TenSkin™, responds like it would in vivo, delivering predictive results that contribute to a more efficient development process. The company was founded in 2019 by Robyn Hickerson and Michael Patrick Conneely, with Robyn Hickerson serving as CEO since then.